The Indian market for the sacubitril/valsartan combination appears to be growing in leaps and bounds, suggesting that Novartis AG’s efforts to expand reach and access for its heart failure therapy via partnerships is paying dividends. Nevertheless, the shadow of an ongoing suit for a cut-price version of the product looms.
Novartis’s Entresto (sacubitril/valsartan) is sold as Vymada in India, along with its second brands Cidmus and Azmarda, marketed by





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
